Home/Pipeline/PD-1/VEGF Program

PD-1/VEGF Program

Cancer (unspecified)

Not DisclosedActive

Key Facts

Indication

Cancer (unspecified)

Phase

Not Disclosed

Status

Active

Company

OncoC4

About OncoC4

OncoC4 is a private, clinical-stage biotech focused on novel immuno-oncology and neurodegenerative disease therapeutics. Its core strategy involves targeting both established (CTLA-4, PD-1) and emerging (CD24, Siglec) immune checkpoints with a pipeline of monoclonal antibodies, bispecifics, and antibody-drug conjugates. The company has established a key partnership with BioNTech for its lead CTLA-4 asset and operates with a lean, global team. OncoC4 is positioned in the competitive but high-potential fields of next-generation cancer immunotherapy and neuro-immunology.

View full company profile

Therapeutic Areas

Oncology Neurodegenerative Diseases

Other Cancer (unspecified) Drugs

Drug	Company	Phase	Status
CAR-engineered NK cells	Glycostem	Pre-clinical	Active
Lead Universal CAR-T Candidate	Allogenica	Pre-clinical	Active
ADU-1805	Sairopa	Preclinical	Active
PSC-derived NK Cells	HebeCell	Pre-clinical	Active
mRNA CAR-γδ-T Cell Platform	PhosphoGam	Pre-clinical	Active
R-5780	Rise Therapeutics	Phase 1	Active
Dendritic Cell-Based Cancer Vaccines	Celica Biomedical	Pre-clinical	Active
Oncology Drug Delivery	Sporegen	Pre-clinical	Active